Browse NSDHL

Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass membrane protein Lipid droplet Note=Trafficking through the Golgi is necessary for ER membrane localization.
Domain PF01073 3-beta hydroxysteroid dehydrogenase/isomerase family
Function

Involved in the sequential removal of two C-4 methyl groups in post-squalene cholesterol biosynthesis.

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001942 hair follicle development
GO:0006066 alcohol metabolic process
GO:0006694 steroid biosynthetic process
GO:0006695 cholesterol biosynthetic process
GO:0007224 smoothened signaling pathway
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0008544 epidermis development
GO:0016125 sterol metabolic process
GO:0016126 sterol biosynthetic process
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0043588 skin development
GO:0044283 small molecule biosynthetic process
GO:0046165 alcohol biosynthetic process
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0060674 placenta blood vessel development
GO:0060711 labyrinthine layer development
GO:0060716 labyrinthine layer blood vessel development
GO:0061458 reproductive system development
GO:0098773 skin epidermis development
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1902652 secondary alcohol metabolic process
GO:1902653 secondary alcohol biosynthetic process
Molecular Function GO:0000252 C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity
GO:0003854 3-beta-hydroxy-delta5-steroid dehydrogenase activity
GO:0016229 steroid dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0047012 sterol-4-alpha-carboxylate 3-dehydrogenase (decarboxylating) activity
Cellular Component GO:0005811 lipid particle
> KEGG and Reactome Pathway
 
KEGG hsa00100 Steroid biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-191273: Cholesterol biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NSDHL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NSDHL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.42; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NSDHL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0960.732
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.220.915
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0060.997
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2220.727
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6520.628
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3270.853
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1790.546
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0590.962
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4250.76
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2830.848
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7020.745
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2240.00368
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NSDHL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NSDHL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NSDHL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NSDHL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NSDHL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NSDHL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NSDHL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNSDHL
NameNAD(P) dependent steroid dehydrogenase-like
Aliases XAP104; H105e3; SDR31E1; short chain dehydrogenase/reductase family 31E, member 1; protein H105e3; Sterol-4- ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NSDHL collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NSDHL.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144